Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Merck Ord Shs MKGAF

Alternate Symbol(s): MKKGY

Healthcare

Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Electronics. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and neurodegenerative diseases, developing drugs, diagnostic substances and medical... see more

Add To Watchlist

Recent & Breaking News (OTCPK:MKGAF)

Athinia(TM) expands partnerships to include Tokyo Electron for real-time collaborative analytics of semiconductor fab equipment performance

PR Newswire July 11, 2023

Merck KGaA, Darmstadt, Germany, Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer

PR Newswire March 16, 2021

Merck KGaA, Darmstadt, Germany, to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on 19 November 2020

PR Newswire November 13, 2020

Breakthrough Innovation in Cancer Care From EMD Serono Pipeline to Be Presented at ASCO 2020

PR Newswire May 13, 2020

Merck Invests in Expansion of Manufacturing Capacity for Biotech Medicines

PR Newswire Europe Non Regulatory March 28, 2019

Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine

PR Newswire Asia February 17, 2019

Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer

PR Newswire December 21, 2018

Merck and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer

PR Newswire Europe Non Regulatory December 21, 2018

Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer

PR Newswire November 19, 2018

Global Survey and Documentary Film Expose Emotional Impact of Multiple Sclerosis

Canada NewsWire October 11, 2018

Merck KGaA, Darmstadt, Germany Data at ESMO 2018 Congress Highlight Multiple Therapeutics with Potential to Transform Cancer Care

PR Newswire October 9, 2018

BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study

PR Newswire September 11, 2018

Two-Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab)

PR Newswire June 4, 2018

Merck KGaA, Darmstadt, Germany Data at ASCO 2018 to Showcase Progress and Further Optionality of Oncology Pipeline

PR Newswire May 16, 2018

Merck KGaA to Host Earnings Call

Accesswire May 15, 2018

Mavenclad (Cladribine Tablets) Receives First Approval in the Middle East & Africa Region

PR Newswire Europe Non Regulatory April 9, 2018

Merck KGaA, Darmstadt, Germany webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference

PR Newswire March 26, 2018

Merck KGaA, Darmstadt, Germany to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on 22nd March 2018

PR Newswire March 20, 2018

Merck KGaA, Darmstadt, Germany, Announces Positive Phase IIB Results for Evobrutinib in Relapsing Multiple Sclerosis

PR Newswire March 7, 2018

Mavenclad (Cladribine Tablets) Receives First Approval in Latin America

PR Newswire Europe Non Regulatory February 26, 2018